JPH0567608B2 - - Google Patents
Info
- Publication number
- JPH0567608B2 JPH0567608B2 JP58051201A JP5120183A JPH0567608B2 JP H0567608 B2 JPH0567608 B2 JP H0567608B2 JP 58051201 A JP58051201 A JP 58051201A JP 5120183 A JP5120183 A JP 5120183A JP H0567608 B2 JPH0567608 B2 JP H0567608B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- caries
- myutans
- activity
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004075 cariostatic agent Substances 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 9
- 150000002596 lactones Chemical class 0.000 claims description 8
- 150000001735 carboxylic acids Chemical class 0.000 claims description 5
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 2
- CDJJKTLOZJAGIZ-UHFFFAOYSA-N Tolylacetate Chemical compound CC(=O)OC1=CC=C(C)C=C1 CDJJKTLOZJAGIZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940005667 ethyl salicylate Drugs 0.000 claims description 2
- 229940116837 methyleugenol Drugs 0.000 claims description 2
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 claims description 2
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 claims description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- GHBSPIPJMLAMEP-UHFFFAOYSA-N 6-pentyloxan-2-one Chemical compound CCCCCC1CCCC(=O)O1 GHBSPIPJMLAMEP-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 239000005639 Lauric acid Substances 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 claims 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 claims 1
- SKQYTJLYRIFFCO-UHFFFAOYSA-N delta-Tetradecalactone Chemical compound CCCCCCCCCC1CCCC(=O)O1 SKQYTJLYRIFFCO-UHFFFAOYSA-N 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 1
- 229960002703 undecylenic acid Drugs 0.000 claims 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 claims 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 description 28
- 239000003205 fragrance Substances 0.000 description 23
- 208000002925 dental caries Diseases 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 19
- 239000004615 ingredient Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229920001503 Glucan Polymers 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 230000000675 anti-caries Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241001579869 Phazaca mutans Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- -1 troche Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
Description
〔産業上の利用分野〕
この発明は、抗齲蝕剤、すなわち齲蝕を予防し
またはその進行を阻止する口腔用剤に関するもの
である。
〔従来の技術〕
近年、齲蝕すなわち虫歯の罹患率は著しく増大
しており、大きな社会問題にまで発展している。
一方、これに伴つて齲蝕の原因の研究も進んでお
り、現在の定説では齲蝕の原因は食物中の蔗糖が
齲蝕原因菌の作用により変化を受け不溶性かつ粘
着性のグルカンを生成することにあるとされてい
る。このようにして生成されたグルカンによつて
齲蝕原因菌が歯面に付着して増殖し歯垢を形成す
る。そして、この歯垢をベースとしてその中の細
菌が糖発酵により酸を発生し、その酸により齲蝕
が進行するのである。齲蝕の防止には歯の抵抗性
を高める方法、蔗糖を排除するか、蔗糖に代わる
甘味料を使用する方法、蔗糖より生成する不溶性
のグルカンを分解するかまたはグルカンの生成を
阻止する方法もしくは齲蝕原因菌を撲滅する方法
等が考えられる。上記の方法にはそれぞれ長所欠
点を備えているが齲蝕の本質が齲蝕原因菌による
感染症であるため、この原因となる齲蝕原因菌を
撲滅することが齲蝕防止に最も効果的であると考
えられる。上記の菌としてはストレプトコツカス
ミユータンス(Streptococcus Mutans)やスト
レプトコツカスサングイス(Streptococcus
Sanguis)があげられる。齲蝕防止のためにこの
ような齲蝕原因菌を駆逐しようとするこころみは
これまでも数多くなされている。例えばペニシリ
ンやエリスロマイシン等の抗生物質、齲蝕原因菌
の細胞壁を溶解する細胞壁溶解酵素やシクロヘキ
シジン等の殺菌剤の使用がこころみられている。
しかしながら、これらは口腔内および腸内細菌叢
の撹乱により自然の細菌バランスを壊し、しかも
副作用を惹起するという問題がある。このような
副作用の問題の解決がなされていないため広く用
いられるには到つていない。
〔発明が解決しようとする課題〕
このように、もつかのところ齲蝕防止のために
決定的な方法がないのが実情であり、食後、はぶ
らしで清掃するという物理的な方法に勝る予防法
の確立がなされていないのが現状である。
この発明はこのような事情に鑑みなされたもの
で副作用が生じず長期間の連用に耐えうる抗齲蝕
剤の提供をその目的とする。
〔課題を解決すべき手段〕
上記の目的を達成するためこの発明の抗齲蝕剤
は下記の(A)成分、(B)成分、および(C)成分のうち少
なくとも(A)成分を有効成分とするという構成をと
る。
(A) クレジルアセテート、メチルオイゲノール、
ヘリオトロピンおよびエチルサリシレートから
なる群から選択された少なくとも一つの化合
物。
(B) カルボン酸
(C) ラクトン
〔作用〕
本発明者らは、齲蝕の防止を目指して一連の研
究を重ねているうち、ある種の香料に抗菌作用が
あることにヒントを得て、香料を抗齲蝕剤として
用いられないかと厖大な数の香料を対象とし、長
期間に渡つて一連の研究を進めてきた。その結
果、合成香料を構成する香料成分化合物をそのま
ま用いるか、もしくは香料成分化合物とカルボン
酸、ラクトンのような着香料(食品香料)を適宜
に組み合わせると優れた齲蝕原因菌殺菌効果が得
られるようになることを見いだしこの発明に到達
した。
このように、この発明の抗齲蝕剤は、副作用が
全くなく安全性の極めて高い香料成分化合物を抗
齲蝕剤の必須成分として用いるところに最大の特
徴がある。
つぎに、この発明を詳しく説明する。
従来から、香料を構成する香料成分化合物のあ
る種のものには抗菌作用があるという報告が散見
されている。しかしながら、最も強い齲蝕作用を
もつミユータンス菌に対する抗菌活性に関する報
告は皆無である。そこで本発明者らは、先づ第1
段階として何らかの抗菌作用が報告されているか
比較的汎用されている合成香料成分化合物を対象
としミユータンス菌に対する抗菌活性を測定し
た。抗菌活性は、それぞれ上記合成香料成分化合
物を5%のアルコール溶液とし(これを供試成分
とする)、これを5%の蔗糖を含有するハートイ
ンフユージヨン培地に1/100〜1/1000の割合(5
%アルコール溶液((供試成分))濃度が1/100〜
1/1000)になるように添加し、培地が固化したの
ち、ミユータンス菌(ストレプトコツカスミユー
タンスRIMD3125001)を穿刺接種して37℃で72
時間以上培養し、培地中、培地表面における菌の
生育を観察して測定した。抗ミユータンス菌活性
があるものは後記の第1表のとおりである。抗ミ
ユータンス菌活性があるということは、供試成分
を1/1000の割合になるように添加し、37℃で72時
間以上培養した場合においてミユータンス菌の生
育が認められないということである。そして、供
試成分濃度をどんどん希釈してゆき、抗ミユータ
ンス菌活性が認められる最小濃度(有効生育阻止
濃度)の逆数、例えば供試成分濃が1/1000である
ときは、その逆数の1000を抗ミユータンス菌活性
値として示した。対象用として厚朴エキス、厚朴
エキスの有効成分であるマグノロールならびにミ
ユータンス菌に対する殺菌作用をもつ抗生物質エ
リスロマイシンを用い、同様の実験を行つて第1
表に併せて示した。第1表に揚げる合成香料成分
化合物は、抗齲蝕用剤として知られている厚朴エ
キス(特開昭57−85319参照)と同等の優れた抗
ミユータンス菌活性を示している。
このように、合成香料成分化合物が極めて抗ミ
ユータンス菌活性に富んでいることより探索範囲
をカルボン酸およびラクトンのような着香料の分
野まで広げて抗ミユータンス菌活性のある物質を
調べた。その結果は後記の第2表のとおりであ
る。第2表に揚げるカルボン酸およびラクトン群
が極めて高い抗ミユータンス菌活性を備えてい
た。
つぎに、上記第1表および第2表に示す香料成
分を混合してその抗ミユータンス菌活性を調べ
た。その結果は後記の第3表に示すとおりであ
り、それぞれ第1表および第2表の香料成分のミ
ユータンス菌活性値の相加平均よりも高い抗ミユ
ータンス菌活性値が得られた。これは第1表およ
び第2表に示す香料成分を混合することにより大
きな相乗効果が得られることを示している。すな
わち、一般に、香料成分は単独で使用されること
は稀であり、各種の成分を調合して所望の香りの
混合香料をつくり、これを使用することが行われ
ている。したがつて、第1表および第2表に示す
香料成分を混合して用いることにより第3表に示
すような大きな相乗効果が得られるようになると
いうことは実用上極めて有効である。
このように、この発明の抗齲蝕剤は、食品業界
等で幅広く、実際に使用されている安全性の高い
香料成分化合物からなるため副作用は全く生じな
い。すなわち、この発明の抗齲蝕剤は抗生物質で
あるエリスロマイシンに比べればその抗齲蝕作用
がやや低いが、この発明の抗齲蝕剤は抗生物質で
はないため抗生物質にみられるような副作用(体
内微生物相の撹乱、耐性菌の出現)がなく、長期
間連用しても全く問題はない。そのうえ、この発
明の抗齲蝕剤は合成香料、カルボン酸、ラクトン
等幅広い範囲の香料成分化合物からなるため、適
宜の香料成分化合物を組み合わせて、抗齲蝕剤の
添加の対象となる品物に任意の好ましい風味を付
与しうるようになる。この効果は、抗齲蝕剤の投
与がある程度長期間に渡ること、また、ことに齲
蝕予防のためには歯牙の萌出がはじまる1才前後
からの幼児における投与が望ましいことも考え合
わせると臨床実用上、きわめて有用性の高いもの
である。
さらに、この発明の抗齲蝕剤は極めて低濃度で
ミユータンス菌の生育を阻止することができるた
め、微量の使用量で大きな抗齲蝕効果を得ること
ができる。
このように、この発明の抗齲蝕剤は、香料成分
化合物であつてしかも微量の使用量で優れた抗齲
蝕効果が得られるため、うがい薬、トローチ、は
みがき、チユーインガム等を賦香すると同時に抗
齲蝕効果も発揮しうるのである。そして、その使
用により、従来の抗生物質のような副作用が全く
生じないのであり、長期間の連用に充分に耐えう
る極めて実用性の高いものである。しかも、この
発明の抗齲蝕剤は、そのなかにすでに抗菌作用を
有するものとして知られているものを含んでいる
が、それらは大腸菌、赤痢菌などの病原菌に対し
て抗菌作用を有していることが知られているだけ
であり、ミユータンス菌のような特殊な菌(連鎖
状球菌の分類いずれにも属しない)に対する抗菌
作用に対しては全く知られていないため、これま
でのものから予見しえない優れた効果を奏しうる
といえるものである。
そして、この発明の抗齲蝕剤は、上記うがい
薬、トローチ、はみがき等にそのまま所定量、添
加混合するだけで有効である。例えば、うがい薬
の場合には、抗齲蝕剤を5%のアルコール溶液と
し、これを10%の蔗糖溶液に、1/3000〜1/5000の
濃度(供試成分濃度として、以下同じ)になるよ
う添加すればよい。
[Industrial Field of Application] This invention relates to an anti-caries agent, that is, an oral agent that prevents or inhibits the progression of caries. [Prior Art] In recent years, the prevalence of dental caries, or tooth decay, has increased significantly and has developed into a major social problem.
At the same time, research into the causes of caries is progressing, and the current theory is that the sucrose in food undergoes changes due to the action of caries-causing bacteria, producing insoluble and sticky glucans. It is said that Due to the glucan thus produced, caries-causing bacteria adhere to the tooth surface and multiply to form dental plaque. Using this plaque as a base, bacteria within it generate acid through sugar fermentation, and this acid causes dental caries to progress. To prevent dental caries, there are methods to increase the resistance of teeth, to eliminate sucrose or to use sweeteners instead of sucrose, to break down insoluble glucan produced from sucrose, or to inhibit the production of glucan, or to prevent caries. Possible methods include eradicating the causative bacteria. Each of the above methods has advantages and disadvantages, but since caries is essentially an infection caused by caries-causing bacteria, eradicating the caries-causing bacteria is considered to be the most effective way to prevent caries. . The above bacteria include Streptococcus mutans and Streptococcus sanguis.
Sanguis). Many attempts have been made to eliminate such caries-causing bacteria in order to prevent caries. For example, efforts are being made to use antibiotics such as penicillin and erythromycin, cell wall lytic enzymes that dissolve the cell walls of caries-causing bacteria, and bactericidal agents such as cyclohexidine.
However, these have the problem of disrupting the natural bacterial balance by disturbing the oral and intestinal flora, and causing side effects. Since the problem of such side effects has not been solved, it has not been widely used. [Problem to be solved by the invention] As described above, the reality is that there is no definitive method for preventing caries, and there is no prevention method that is better than the physical method of cleaning with a towel after eating. The current situation is that no law has been established. The present invention was made in view of the above circumstances, and an object of the present invention is to provide an anti-caries agent that does not cause side effects and can withstand long-term use. [Means to Solve the Problem] In order to achieve the above object, the anti-caries agent of the present invention contains at least component (A) as an active ingredient among the following components (A), (B), and (C). The structure is as follows. (A) cresyl acetate, methyleugenol,
At least one compound selected from the group consisting of heliotropin and ethyl salicylate. (B) Carboxylic acid (C) Lactone [Action] While conducting a series of studies aimed at preventing dental caries, the present inventors got a hint from the fact that certain fragrances have antibacterial effects, and developed a fragrance We have conducted a series of long-term studies on a huge number of fragrances to see if they could be used as anti-caries agents. As a result, it appears that excellent caries-causing bacteria sterilization effects can be obtained by using the fragrance component compounds that make up synthetic fragrances as they are, or by appropriately combining them with flavoring agents (food flavorings) such as carboxylic acids and lactones. This invention was achieved by discovering that As described above, the greatest feature of the anti-caries agent of the present invention is that it uses an extremely safe fragrance ingredient compound with no side effects as an essential component of the anti-caries agent. Next, this invention will be explained in detail. BACKGROUND ART There have been reports here and there that certain types of fragrance component compounds constituting fragrances have antibacterial effects. However, there are no reports regarding antibacterial activity against Myutans bacteria, which has the strongest cariogenic effect. Therefore, the present inventors first
The antibacterial activity against B. myutans was measured for synthetic fragrance compounds that have been reported to have some kind of antibacterial effect or are relatively widely used. The antibacterial activity was determined by making a 5% alcohol solution of each of the above synthetic fragrance ingredients (this is used as the test ingredient), and adding 1/100 to 1/1000 of this to a heart infusion medium containing 5% sucrose. Percentage (5
% alcohol solution ((test component)) concentration is 1/100~
After the medium had solidified, S. myutans (Streptococcus miutans RIMD3125001) was inoculated by puncture and incubated at 37℃ for 72 hours.
After culturing for more than an hour, the growth of the bacteria in the medium and on the surface of the medium was observed and measured. Those exhibiting antimyutans activity are shown in Table 1 below. Having anti-Myutans activity means that no growth of Myutans bacteria is observed when the test component is added at a ratio of 1/1000 and cultured at 37°C for 72 hours or more. Then, the concentration of the test component is gradually diluted, and the reciprocal of the minimum concentration (effective growth inhibitory concentration) at which anti-myutans activity is observed, for example, if the concentration of the test component is 1/1000, the reciprocal is 1000. It was shown as the antimyutans activity value. A similar experiment was conducted using Koboku extract, magnolol, which is an active ingredient of Koboku extract, and erythromycin, an antibiotic that has a bactericidal effect against P. myutans bacteria.
It is also shown in the table. The synthetic fragrance component compounds listed in Table 1 exhibit excellent antimyutans activity equivalent to that of Koboku extract (see JP-A-57-85319), which is known as an anti-caries agent. Since synthetic fragrance ingredients are extremely rich in anti-myutans activity, we expanded our search to the field of flavoring agents such as carboxylic acids and lactones to investigate substances with anti-myutans activity. The results are shown in Table 2 below. The carboxylic acids and lactones listed in Table 2 had extremely high antimyutans activity. Next, the fragrance ingredients shown in Tables 1 and 2 above were mixed and their antimyutans activity was examined. The results are shown in Table 3 below, and anti-myutans activity values higher than the arithmetic mean of the activity values of the anti-myutans bacteria of the fragrance ingredients in Tables 1 and 2 were obtained. This shows that a great synergistic effect can be obtained by mixing the fragrance ingredients shown in Tables 1 and 2. That is, in general, fragrance ingredients are rarely used alone, and various ingredients are mixed to create a mixed fragrance with a desired fragrance, which is then used. Therefore, it is extremely effective in practice that the large synergistic effects shown in Table 3 can be obtained by mixing and using the fragrance ingredients shown in Tables 1 and 2. As described above, the anti-caries agent of the present invention does not cause any side effects because it is composed of a highly safe flavor component compound that is widely and actually used in the food industry and the like. In other words, the anti-caries agent of this invention has a slightly lower anti-caries effect than the antibiotic erythromycin, but since the anti-caries agent of this invention is not an antibiotic, it does not cause side effects (in vivo microflora) that are seen with antibiotics. (disturbance of bacteria, emergence of resistant bacteria), and there is no problem at all even when used continuously for a long period of time. Moreover, since the anti-caries agent of the present invention is composed of a wide range of fragrance components such as synthetic fragrances, carboxylic acids, lactones, etc., suitable fragrance components can be combined with any desired desired product to which the anti-caries agent is added. It can add flavor. This effect is practical in clinical practice, considering that the administration of anti-caries agents lasts for a certain period of time, and that it is especially desirable to administer them to infants from around 1 year of age, when teeth begin to erupt, to prevent caries. , is extremely useful. Furthermore, since the anti-caries agent of the present invention can inhibit the growth of Myutans bacteria at extremely low concentrations, a large anti-caries effect can be obtained with a small amount of use. As described above, the anti-caries agent of the present invention is a fragrance ingredient compound and has an excellent anti-caries effect even when used in a small amount. It can also be effective. Moreover, its use does not cause any side effects unlike those of conventional antibiotics, and it is highly practical as it can withstand long-term continuous use. Moreover, the anti-caries agent of the present invention contains substances already known to have antibacterial effects, and they have antibacterial effects against pathogenic bacteria such as Escherichia coli and Shigella. However, there is nothing known about its antibacterial effect on special bacteria such as S. myutans (which does not belong to any of the streptococcal classifications), so it cannot be predicted based on what has been reported so far. It can be said that it can produce unprecedented effects. The anti-caries agent of the present invention is effective simply by adding a predetermined amount to the above-mentioned mouthwash, troche, toothpaste, etc. as it is. For example, in the case of mouthwash, the anti-caries agent is made into a 5% alcohol solution, and this is added to a 10% sucrose solution to give a concentration of 1/3000 to 1/5000 (as the concentration of the test ingredient, the same applies hereinafter). Just add it like this.
【表】【table】
【表】【table】
【表】【table】
【表】
つぎに、実施例について説明する。
以下の実施例では混合により優れた相乗効果が
得られる第3表の混合物を用いて行つた。
実施例 1
第3表に記載されたNo.1の混合物を対象とし、
これのミユータンス菌活性を求めたところ、ミユ
ータンス菌に対する有効生育阻止濃度は1/3000
(抗ミユータンス菌活性3000)であつた。このNo.
1混合物の5%アルコール溶液を濃度10%の蔗糖
溶液に1/3000の濃度になるよう添加して口に含ん
でも違和感および刺激は全く感じられなかつた。
実施例 2
第3表のNo.2の混合物を対象とし、これのミユ
ータンス菌に対する有効生育阻止濃度を調べたと
ころその有効生育阻止濃度は1/4000(抗ミユータ
ンス菌活性4000)であつた。この混合物の5%ア
ルコール溶液を濃度10%の蔗糖溶液に1/4000の濃
度になるよう添加して口に含んでも違和感および
刺激は全く感じられなかつた。
実施例 3
第3表のNo.3の混合物を対象とし、そのミユー
タンス菌に対する有効生育阻止濃度を求めた。こ
のものの有効生育阻止濃度は1/4000(抗ミユータ
ンス菌活性4000)であつた。この混合物の5%ア
ルコール溶液を濃度10%の蔗糖溶液に1/4000の濃
度になるよう添加して口に含んでも違和感および
刺激は全く感じられなかつた。
実施例 4
第3表のNo.4の混合物を対象とし、この混合物
のミユータンス菌に対する有効生育阻止濃度を求
めた。その結果、有効生育阻止濃度は1/5000(抗
ミユータンス菌活性5000)であつた。そして、こ
のものの5%アルコール溶液を濃度10%の蔗糖溶
液に1/5000の濃度になるよう添加して口に含んで
も違和感および刺激は全く感じられなかつた。[Table] Next, examples will be described. The following examples were carried out using the mixtures of Table 3, which give excellent synergistic effects upon mixing. Example 1 Targeting the No. 1 mixture listed in Table 3,
When the activity of B. myutans was determined, the effective growth-inhibiting concentration against B. myutans was 1/3000.
(Anti-myutans activity 3000). This No.
Even when a 5% alcohol solution of 1 mixture was added to a 10% sucrose solution to a concentration of 1/3000 and put into the mouth, no discomfort or irritation was felt at all. Example 2 The effective growth-inhibiting concentration against B. myutans was investigated using the mixture No. 2 in Table 3, and the effective growth-inhibiting concentration was found to be 1/4000 (anti-Myutans activity: 4000). Even when a 5% alcohol solution of this mixture was added to a 10% sucrose solution to a concentration of 1/4000 and placed in the mouth, no discomfort or irritation was felt at all. Example 3 Targeting the mixture No. 3 in Table 3, its effective growth-inhibiting concentration against P. myutans was determined. The effective growth-inhibiting concentration of this product was 1/4000 (anti-Myutans activity 4000). Even when a 5% alcohol solution of this mixture was added to a 10% sucrose solution to a concentration of 1/4000 and placed in the mouth, no discomfort or irritation was felt at all. Example 4 Targeting the mixture No. 4 in Table 3, the effective growth-inhibiting concentration of this mixture against B. mutans was determined. As a result, the effective growth-inhibiting concentration was 1/5000 (anti-Myutans activity 5000). Even when a 5% alcohol solution of this product was added to a 10% sucrose solution to a concentration of 1/5000 and placed in the mouth, no discomfort or irritation was felt at all.
Claims (1)
少なくとも(A)成分を有効成分とする抗齲蝕剤。 (A) クレジルアセテート、メチルオイゲノール、
ヘリオトロピンおよびエチルサリシレートから
なる群から選択された少なくとも一つの化合
物。 (B) カルボン酸 (C) ラクトン 2 カルボン酸が、カプリン酸、ラウリン酸、ミ
リスチン酸、パルミチン酸、ステアリン酸、オレ
イン酸、リノール酸、ロジン酸、バニリン酸、ウ
ンデカン酸、ウンデシレン酸およびエナント酸か
らなる群から選ばれた少なくとも一つのカルボン
酸である特許請求の範囲第1項記載の抗齲蝕剤。 3 ラクトンが、d−デカラクトン、d−ドデカ
ラクトン、d−ウンデカラクトン、d−トリデカ
ラクトンおよびd−テトラデカラクトンからなる
群から選ばれた少なくとも一つのラクトンである
特許請求の範囲第1項記載の抗齲蝕剤。[Scope of Claims] 1. An anti-caries agent containing at least component (A) among the following components (A), (B), and (C) as an active ingredient. (A) cresyl acetate, methyleugenol,
At least one compound selected from the group consisting of heliotropin and ethyl salicylate. (B) Carboxylic acid (C) Lactone 2 Carboxylic acids are derived from capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, rosin acid, vanillic acid, undecanoic acid, undecylenic acid and enanthic acid. The anti-caries agent according to claim 1, which is at least one carboxylic acid selected from the group consisting of: 3. Claim 1, wherein the lactone is at least one lactone selected from the group consisting of d-decalactone, d-dodecalactone, d-undecalactone, d-tridecalactone, and d-tetradecalactone. Anti-caries agents as described.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5120183A JPS59175423A (en) | 1983-03-26 | 1983-03-26 | Cariostatic agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5120183A JPS59175423A (en) | 1983-03-26 | 1983-03-26 | Cariostatic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS59175423A JPS59175423A (en) | 1984-10-04 |
JPH0567608B2 true JPH0567608B2 (en) | 1993-09-27 |
Family
ID=12880276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5120183A Granted JPS59175423A (en) | 1983-03-26 | 1983-03-26 | Cariostatic agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS59175423A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE551053T1 (en) | 2002-09-26 | 2012-04-15 | Mandom Corp | ANTISEPTIC BACTERICIDES, AND COSMETICS, DRUGS AND FOODS CONTAINING THE ANTISEPTIC BACTERICIDES |
ATE550018T1 (en) | 2002-09-26 | 2012-04-15 | Mandom Corp | ANTISEPTIC BACTERICIDES AND COSMETICS, MEDICINAL PRODUCTS AND FOODS CONTAINING THE ANTISEPTIC BACTERICIDES |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5929619A (en) * | 1982-08-11 | 1984-02-16 | T Hasegawa Co Ltd | Preventing agent for carious tooth |
JPS5929618A (en) * | 1982-08-11 | 1984-02-16 | T Hasegawa Co Ltd | Preventing agent for carious tooth |
-
1983
- 1983-03-26 JP JP5120183A patent/JPS59175423A/en active Granted
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5929619A (en) * | 1982-08-11 | 1984-02-16 | T Hasegawa Co Ltd | Preventing agent for carious tooth |
JPS5929618A (en) * | 1982-08-11 | 1984-02-16 | T Hasegawa Co Ltd | Preventing agent for carious tooth |
Also Published As
Publication number | Publication date |
---|---|
JPS59175423A (en) | 1984-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080125496A1 (en) | Antimicrobial flavor and oral care composition containing the same | |
Muroi et al. | Bactericidal activity of anacardic acids against Streptococcus mutans and their potentiation | |
JPH0138084B2 (en) | ||
JPH0140005B2 (en) | ||
JP3614479B2 (en) | Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them | |
JPS61171423A (en) | Drug for alleviating dental caries and periodontosis | |
JPH0432047B2 (en) | ||
JPH0217524B2 (en) | ||
JP7351296B2 (en) | Oral flora improving agent and oral composition | |
JPH0639375B2 (en) | Anti-caries agent | |
KR20150061762A (en) | Oral composition having anti-detal caries efficacy | |
KR20170111640A (en) | Composition Containing Monolaurin for Preventing Biofilm Formation of Streptococcus mutans | |
JP6249438B2 (en) | Oral hygiene improving active composition | |
JPH0567608B2 (en) | ||
US20040265247A1 (en) | Mouth rinse composition | |
JPH07116059B2 (en) | Anti-periodontal disease composition | |
JP2019011268A (en) | Oral composition comprising oral cavity normal flora regulator, oral care products and foods | |
WO2021079921A1 (en) | Growth inhibitor for pathogenic bacteria in oral cavity, oral microflora improver, and composition for oral cavity | |
JPH0320364B2 (en) | ||
KR101295242B1 (en) | Antibacterial Composition for Inhibiting Oral Bacteria comprising extract of Dianthus superbus | |
JPS5835484B2 (en) | Oral composition | |
KR102575768B1 (en) | Natural Edible Film Compositions for Preventing or Improving Oral Diseases and Uses Thereof | |
JP7362417B2 (en) | Growth inhibitors, oral compositions, and promoters of oral pathogenic bacteria | |
JP6921655B2 (en) | Protease inhibitors, biofilm formation inhibitors, and oral compositions | |
JPS641441B2 (en) |